Bu dergideki yayınlar

1 →
  • ArticleYayıncıda açık erişim2020
    Poor biological factors and prognosis of interval breast cancers: Long-term results of bahçeşehir (Istanbul) breast cancer screening project in Turkey

    Cabioglu, Neslihan; Gürdal, Sibel Özkan; Kayhan, Arda; Özaydın, Nilüfer; Şahin, Cennet; Can, Ömür; Özçınar, Beyza; Aykuter, Gönül; Vatandaş, Gülçin; Aribal, Erkin

    PURPOSE The Turkish Bahçeşehir Breast Cancer Screening Project was a 10-year, organized, population-based screening program carried out in Bahçeşehir county, Istanbul. Our aim was to examine the biologic features and outcome of screen-detected and interval breast cancers during the 10-year study period. METHODS Between 2009 and 2019, 2-view mammograms were obtained at 2-year intervals for women aged 40 to 69 years. Clinicopathological characteristics including ER, PR, HER2-neu, and Ki-67 status were analyzed for those diagnosed with breast cancer. RESULTS In 8,758 screened women, 131 breast cancers (1.5%) were detected. The majority of patients (82.3%) had prognostic stage 0-I disease. Contrarily, patients with interval cancers (n = 15; 11.4%) were more likely to have a worse prognostic stage (II-IV disease; odds ratio [OR], 3.59, 95% CI, 0.9 to 14.5) and high Ki-67 scores (OR, 3.14; 95% CI, 0.9 to 11.2). Interval cancers detected within 1 year were more likely to have a luminal B (57.1% v 31.9%) and triple-negative (14.3% v 1%) subtype and less likely to have a luminal A subtype (28.6% v 61.5%; P =.04). Patients with interval cancers had a poor outcome in 10-year disease-specific (DSS) and disease-free survival (DFS) compared with those with screen-detected cancers (DSS: 68.2% v 98.1%, P =.002; DFS: 78.6% v 96.5%, P =.011). CONCLUSION Our findings suggest the majority of screen-detected breast cancers exhibited a luminal A subtype profile with an excellent prognosis. However, interval cancers were more likely to have aggressive subtypes such as luminal B subtype or triple-negative cancers associated with a poor prognosis requiring other preventive strategies.

    RDL Kalıcı Kaydıİncele
Tam Kayıt
AlanDeğerDil
creativeworkseries.issn2687-8941
dc.date.accessioned2026-10-20T15:39:59.069073752Z
dc.date.available2026-10-20T15:39:59.069073752Z
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/24461
dc.publisherAmerican Society of Clinical Oncology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleJCO Global Oncology
dspace.entity.typeJournal